|
|
|
| home > pmps > autumn 2003 > generics boards surfing the new wave in contract manufacturing services |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
With the rapidly rising tide in sales of unbranded medicines, are the holders of expiring patents for branded products about to find themselves stranded on the rocks or simply getting wet feet?
Recent developments at the WTO and changes in Europe's pharmaceutical legislation could drive suppliers of generics to outsource development and production to countries like Portugal, where they can take the necessary steps before the tide turns for their branded or innovator competition.
With about 35 per cent of pharma's lucrative blockbusters coming off patent by 2007, the rising tide of generics will experience a big surge driving the managerial boards of generics suppliers to get to market as early as possible, preferably as soon as the bell-buoy rings 'time up'.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Signant Health Debuts Standardized Electronic Seizure Diary Developed in Collaboration with The Epilepsy Study Consortium
PHILADELPHIA, PA – January 17, 2023 – Signant Health, the leader in evidence generation for modern clinical trials, introduced today a novel electronic diary (eDiary) data capture solution designed to simplify the experience for patients and research sites participating in epilepsy trials while ensuring robust outcome assessment data to support trial endpoints. Developed in collaboration with The Epilepsy Study Consortium (TESC), the new patient-reported outcome measure offers clinical research sponsors and organizations a standardized solution to capture common seizure-data elements with high-quality data.
More info >> |
|
 |
White Papers |
 |
|
Accelerating the Time from DNA to Material
Merck
Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >> |
|
|
